Os Therapies Incorporated (OSTX)

Jan 16, 2025, 4:06 PM EST - 1 day ago

OS Therapies: A Cheap Mid-Stage Biotech Carrying Listeria-Based Immunotherapy

Jan 15, 2025, 11:18 AM EST - 2 days ago

Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?

Jan 15, 2025, 7:40 AM EST - 2 days ago

OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

Jan 2, 2025, 11:16 AM EST - 15 days ago

OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Dec 31, 2024, 3:38 PM EST - 17 days ago

OS Therapies Announces Closing of $6 Million Private Placement

Dec 26, 2024, 10:01 AM EST - 22 days ago

OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online

Dec 24, 2024, 9:32 AM EST - 24 days ago

OS Therapies Announces Pricing of $6 Million Private Placement

Nov 15, 2024, 9:47 AM EST - 2 months ago

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 7:00 AM EST - 2 months ago

OS Therapies to Present at The Spartan Capital Investor Conference

Oct 30, 2024, 8:51 AM EDT - 2 months ago

Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on October 30

Oct 28, 2024, 4:44 PM EDT - 2 months ago

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

Oct 24, 2024, 8:46 AM EDT - 3 months ago

OS Therapies to Present at the LD Micro Main Event XVII

Oct 17, 2024, 9:22 AM EDT - 3 months ago

OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Oct 3, 2024, 12:31 PM EDT - 3 months ago

OSTX CEO: "We Have a Lot of Milestones Coming" in Tumor Research

Oct 3, 2024, 8:00 AM EDT - 3 months ago

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

Sep 13, 2024, 8:09 AM EDT - 4 months ago

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

Sep 11, 2024, 8:15 AM EDT - 4 months ago

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

Sep 5, 2024, 8:22 AM EDT - 4 months ago

OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference

Aug 29, 2024, 7:53 AM EDT - 5 months ago

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose

Aug 22, 2024, 8:00 AM EDT - 5 months ago

OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board

Aug 22, 2024, 6:00 AM EDT - 5 months ago

OS Therapies Clarifies CUSIP of Common Stock

Aug 15, 2024, 8:30 AM EDT - 5 months ago

OS Therapies Reports Second Quarter 2024 Financial Results

Aug 9, 2024, 9:00 AM EDT - 5 months ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CANF

Aug 6, 2024, 8:35 AM EDT - 5 months ago

OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board

Aug 3, 2024, 12:30 AM EDT - 5 months ago

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

ACTU GFL

Aug 2, 2024, 8:55 AM EDT - 6 months ago

OS Therapies Forms Osteosarcoma Patient Advocacy Advisory Board

Jul 31, 2024, 6:21 PM EDT - 6 months ago

OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”

Jul 24, 2024, 10:48 AM EDT - 6 months ago

OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer

Jun 3, 2024, 12:44 PM EDT - 8 months ago

OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma